Call for Abstracts

Notification email was sent to speakers.

1. 1. These guidelines are limited to non-Japanese ophthalmologists living outside of Japan who would like to submit abstracts as "international members".
2. 2. All abstract applicants are required to create a user account first.
3. 3. Once the submission is completed, you will receive automatically delivered e-mail confirming the receipt of your abstract. If you do not receive above e-mail within 24 hours after submission, please contact the Conference Secretariat (76ringan@jtbcom.co.jp).
4. 4. Abstract number will be generated automatically when an abstract is submitted. For changes, withdrawal and additional submission of abstract, please log in with your ID and password by clicking "Abstract Submission" at the bottom of this page.

1. 1. Select the style of presentation
   ● Free Paper Presentation:
   Computer-based presentation only (film slides or videotapes are not allowed)
   ● Poster Presentation:
   Discussion in the Poster/Exhibition Hall
   ※Please note that 76th RINGAN covers clinical and clinically relevant basic content and does not adopt purely basic content.
2. 2. Select an appropriate category from the following list

   01	Cornea, Conjunctiva
   02	Lens, Cataract
   03	Glaucoma
   04	Retina, Vitreous body
   05	Ocular Inflammation, Infection, Uvea
   06	Strabismus, Amblyopia, Pediatric Ophthalmology, Neuro-Ophthalmology
   07	Refraction, Visual Function
   08	Tumor, Orbit, Eyelid, Lacrimal Functional Unit, Pathology, Pharmacology
   09	Low Vision, Color Vision, Electrophysiology
   10	Medical Services, Medical Politics, Others

3. 3. Review Code
   Select one each for RC1 and RC 2 which is mandatory.
   RC3 is required for only who have chosen “4. Retina, Vitreous body” as your category.　

List of Review Code

Presenting at an academic conference is considered to be an act with the purpose of publicizing it as research, and most of the acts are assumed to be conducted as research, not as part of medical treatment. Therefore, ethical review is required even for retrospective studies that do not involve intervention or invasion, except for case reports that are excluded in the guidelines. However, in view of the fact that there are quite a few submissions from facilities that do not have an ethics review committee, etc., it is possible to submit a subject on the condition that the approval of the ethics review committee, etc. is obtained by the time of the conference presentation, even if the subject is under review at the time of submission.

The first author (presenter) of a general presentation should be an international member of the Japanese Ophthalmological Society. Non-members at the time of application are eligible to submit an application and will be granted international membership after acceptance of abstract, endorsement from the presidents and approval by the Board. For further information on international membership, please see here.

1. 1. Papers that have been or will be presented in other academic meetings in Japan or that have already been published in Japan cannot be accepted.
2. 2. A presenter may make only one general presentation, as the first author.
3. 3. The title should be no longer than 80 characters including spaces, affiliation should be concise and the abstract no longer than 1200 characters including spaces. The shortened title should be no longer than 30 characters including spaces.
4. 4. The abstract should be structured with the following headings:,- Objective, Subjects and Methods, Results, and Conclusions, in that order. For case reports and invention or improvement of techniques and devices, the headings should be appropriately changed (for example, for case reports, Introduction, Cases, Discussion and, if relevant, Conclusions).
5. 5. Methods, Results, etc. should be described clearly, with numerical values and the statistical analysis methods used, where possible. Invention or improvement of techniques and devices should also be described clearly.
6. 6. The Conclusion and Discussion should correspond to the Results described.
7. 7. Common names should be used for chemicals. Trade names should be given (……^®) after the common names, if necessary (Example: timolol maleate [Timoptol^®]).
8. 8. Presentations, abstracts and presentation data must be prepared in English.
9. 9. See below for declaration of conflict of interests.
10. 10. On abstract submission form, please select whether you have obtained an approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
11. 11. Regarding an approval of the animal research and ethics committee,
    e.g. IACUC, please select whether you have obtained an approval of the committee or not necessary on the abstract submission form. The author is not required to mention it in the abstract body.
12. 12. On abstract submission form, please select whether you have obtained an informed consent or if it is not necessary. This does not need to be stated in the abstract text.

1. 1. When a duplicate submission (presentation) is suspected, please contact the Committee for Judging Duplicate Presentations of the Japanese Ophthalmological Society in advance.
2. 2. When a duplicate submission (presentation) is confirmed after the registration deadline, presentations by the author (presenter) and co-authors (co-presenters) of the abstract may be temporarily suspended. In addition, their names may also be published in the Japanese Journal of Ophthalmology.
3. 3. The content of the abstract and its description are equally evaluated by peer review, and revisions are not allowed after the registration deadline.
4. 4. When the presentation includes part of the research conducted by multiple institutions, agreement of the persons concerned should be obtained, and the content of the agreement should be described in the Abstract.
5. 5. Meaningless rhetoric, prefixes (for example, Mr., Ms., Prof. and Dr.) inappropriate for academic papers, should not be used.
6. 6. Abstracts without data in the Results section, such as those that only state “will be investigated" and “we describe…," may be rejected.
7. 7. Conclusions should not be drawn from any content(s) not described in the Results.
8. 8. The number of authors is not limited. However, if the number is 13 or more, the conference secretariat must be informed.
9. 9. Withdrawal and revision after the registration deadline are not allowed under any circumstances.

When making a presentation at the Annual Meeting of the Japanese Ophthalmological Society and the Annual Congress of Japan Clinical Ophthalmology, the authors have to report any conflict of interest based on “the rules for conflict of interest of Japanese Ophthalmological Society." If the presentation is accepted, the category of conflict of interest and company names must be disclosed in the slide and poster for presentation, based on “the rules for conflict of interest of Japanese Ophthalmological Society."

A. Presentations to Which These Rules are Applicable

These rules are applicable to all presentations, including those in Co-Sponsored Seminars, Special Lectures, Invited Lectures, Symposia, Instruction Courses, General Presentations (including posters), etc.,

B. Report on Conflict of Interest at Abstract Submission

Report the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation. If conflict of interest is “present," enter the category, class and company names after each author's name in the entry field of “Conflict of Interest" on the abstract submission form. If conflict of interest is absent, enter “category N." Confirm the declaration is correct prior to the registration. Categories and classes are as follows.

1. 1. Category

   F (Financial Support):

   In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.

   (*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.

   I (Personal Financial Interest):

   In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.

   E (Employee):

   In the case where the author is an employee of an interested company.

   C (Consultant):

   In the case where the author is currently, or was within the past three years, a consultant of an interested company.

   P (Patent):

   In the case where the author holds a patent or is in the process of applying for a patent.

   R :

   In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
   

   (*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.

2. 2. Class
   1. 1. 0 yen
   2. 2. From 1 to less than 500,000 yen
   3. 3. From 500,000 to 5,000,000 yen
   4. 4. Over 5,000,000 yen
   * Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.

1. Abstract:
   The presence or absence of conflict of interest to be disclosed for the author (including co-authors) will be automatically shown at the end of the abstract, according to “the detailed rules of the standard for disclosure in the Japanese Ophthalmological Society." For categories F, C and R, only class IV (over 5,000,000 yen) will be correspond to “presence".
2. Slide and poster:
   

   If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide and at the end of the poster. For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed.

   * In the case of "Category P" (the author holds a patent or is in the process of applying for a patent), the company name need not to described.
   If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
   Thank you for your cooperation. Please contact the conference secretariat for any questions by e-mail or FAX (not by telephone).

"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes. The registration process for applications has been commissioned to c/o JTB Communication Design, Inc. in order to facilitate management operations.

For registration confirmation, notification will be sent to the registered e-mail address. If you do not receive notification at the registered e-mail address within 24 hours, please inform the conference secretariat. For submissions (general presentations), notification of acceptance or rejection will be sent to the registered e-mail address around End of July, 2022 (Tentative).
If payment of 1) The International Membership fee for JOS, and 2) The registration fee for the 76th RINGAN are not completed by the pre-registration deadline, your abstract will be considered as having been withdrawn. We will inform you of the payment details in our notification email.